PT  - JOURNAL ARTICLE
AU  - Gimano D Amatngalim
AU  - Lisa W Rodenburg
AU  - Bente L Aalbers
AU  - Henriette HM Raeven
AU  - Ellen M Aarts
AU  - Dounia Sarhane
AU  - Sacha Spelier
AU  - Juliet W Lefferts
AU  - Iris AL Silva
AU  - Wilco Nijenhuis
AU  - Sacha Vrendenbarg
AU  - Evelien Kruisselbrink
AU  - Jesse E Brunsveld
AU  - Cornelis M van Drunen
AU  - Sabine Michel
AU  - Karin M de Winter-de Groot
AU  - Harry G Heijerman
AU  - Lukas C Kapitein
AU  - Magarida D Amaral
AU  - Cornelis K van der Ent
AU  - Jeffrey M Beekman
TI  - Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia
AID  - 10.26508/lsa.202101320
DP  - 2022 Dec 01
TA  - Life Science Alliance
PG  - e202101320
VI  - 5
IP  - 12
4099  - https://www.life-science-alliance.org/content/5/12/e202101320.short
4100  - https://www.life-science-alliance.org/content/5/12/e202101320.full
SO  - Life Sci. Alliance2022 Dec 01; 5
AB  - Cystic fibrosis is caused by genetic defects that impair the CFTR channel in airway epithelial cells. These defects may be overcome by specific CFTR modulating drugs, for which the efficacy can be predicted in a personalized manner using 3D nasal-brushing–derived airway organoids in a forskolin-induced swelling assay. Despite of this, previously described CFTR function assays in 3D airway organoids were not fully optimal, because of inefficient organoid differentiation and limited scalability. In this report, we therefore describe an alternative method of culturing nasal-brushing–derived airway organoids, which are created from an equally differentiated airway epithelial monolayer of a 2D air–liquid interface culture. In addition, we have defined organoid culture conditions, with the growth factor/cytokine combination neuregulin-1β and interleukin-1β, which enabled consistent detection of CFTR modulator responses in nasal-airway organoid cultures from subjects with cystic fibrosis.